Myasthenia gravis (MG) is a chronic autoimmune disease that affects the neuromuscular junction and is characterized by muscle weakness. B cells play a role in MG, and the disease is characterized by the presence of autoantibodies such as anti-AChR and anti-MuSK antibodies. CD-19 target chimeric antigen receptor (CAR) T cells harness the ability of cytotoxic T cells to directly and specifically lyse target cells to effectively deplete both normal and autoreactive B cells in the circulation as well as impacted lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with myasthenia gravis (MG). THIS STUDY IS ENROLLING BY INVITATION ONLY

The goal of this study is to test, in the lab, whether a new treatment may improve cancer killing and bone health in patients with multiple myeloma. Newly diagnosed patients with Multiple Myeloma will meet with PI and/or study staff (face-to-face) and given information about the study. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to find out if adding two drugs called quemliclustat and zimberelimab to the usual chemotherapy drugs can increase the amount of time a person lives with biliary tract cancer without it getting worse. Researchers also want to study the safety and effectiveness of the combination.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Ossium produces cryopreserved hematopoietic progenitor cell bone marrow (HPC, Marrow (Cryopreserved)) recovered from deceased organ donors using good manufacturing practice (GMP) processing, Ossium’s HPC, Marrow (Cryopreserved) is supplied in units suitable for transplantation by infusion, the same procedure used for transplantation of other sources of HPCs, such as live donor BM aspirates, live donor apheresis products, or cord blood. Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product to patients undergoing allogenic bone marrow transplants.Only eligible patients that have been referred by a physician or self-referred to and seen by section of Pediatric Stem Cell Transplant staff will be invited to participate in this program. The subject and donors are known to the study team and they have already been in contact regarding this treatment.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact theIU Clinical Trials Office at Email: iutrials@iu.edu Phone: (317) 278-5632

To compare the achievement rate of MRDneg CR of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapyInterested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This pivotal investigation is a prospective, multicenter, non-randomized, single-arm study to evaluate the safety and effectiveness of the ASG device for the treatment of de novo Type A aortic dissections in patients considered to be high-risk for open surgical repair.THIS STUDY IS ENROLLING BY INVITATION ONLY   - Patients considered to be at high-risk of open surgical repair for aortic dissection will be identified at each site by the Aortic Treatment Team and contacted about study participation.